Long-term efficacy and safety of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): final analysis of the Magnolia (BGB-3111-214) Trial
Authors
Opat, S.Tedeschi, A.
Hu, B.
Linton, Kim M
McKay, P.
Chan, H.
Jin, J.
Sun, M. Y.
Sobieraj-Teague, M.
Zinzani, P. L.
Browett, P. J.
Ke, X. Y.
Portell, C. A.
Thieblemont, C.
Ardeshna, K.
Bijou, F.
Walker, P.
Hawkes, E.
Ho, S. J.
Zhou, K. S.
Liang, Z. Y.
Xu, J. F.
Tankersley, C.
Delarue, R.
Co, M.
Trotman, J.
Affiliation
Monash Health and Monash University, Clayton, Victoria, AustraliaIssue Date
2022
Metadata
Show full item recordCitation
Opat S, Tedeschi A, Hu B, Linton KM, McKay P, Chan H, et al. Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial. Blood. 2022 Nov;140. PubMed PMID: WOS:000893223200234.Journal
BloodDOI
10.1182/blood-2022-163371Additional Links
https://dx.doi.org/10.1182/blood-2022-163371Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2022-163371